Sionna Therapeutics Inc. (SION)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
SION Chart
Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Sionna Therapeutics, Inc. (SION) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Sionna Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 1 | $41 | $4.09 | -$36.91 | -90.02% |
| NA Nizar Araji National Bank Of Canada /FI/ | 2 | $87.98 | $8.16 | -$79.82 | -90.73% |
| BG Bart Gancher Intech Investment Management LLC | 5,218 | $154,669.57 | $21,289.44 | -$133,380.13 | -86.24% |
 John H. Burbank III Passport Capital LLC | 400,000 | $4.18M | $1.61M | -$2.57M | -61.47% |
| CD Charlie Durham Sterling Capital Management LLC | 65 | $2,674.29 | $265.85 | -$2,408.44 | -90.06% |
Sionna Therapeutics Inc. (SION) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sionna Therapeutics Inc. ever had a stock split?
Sionna Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael Cloonan CEO | NASDAQ (NMS) Exchange | 829401108 CUSIP |
| US Country | 59 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Sionna Therapeutics, Inc. is a pioneering biopharmaceutical company focused on developing innovative therapies to improve the lives of patients suffering from cystic fibrosis (CF). By addressing the fundamental issues related to the malfunctioning of the cystic fibrosis transmembrane conductance regulator (CFTR), Sionna aims to enhance treatment paradigms for individuals affected by this genetic disorder. With a strong commitment to advancing research and developing effective medications, Sionna Therapeutics is positioned at the forefront of cystic fibrosis treatment.
Products and Services
- CFTR Modulators
These are tailored medications designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator protein, addressing the root cause of cystic fibrosis. By correcting the defective CFTR protein, these modulators aim to improve lung function and reduce the frequency of pulmonary infections.
- Combination Therapies
Sionna Therapeutics is also focused on developing combination therapies that incorporate multiple drugs to target various aspects of cystic fibrosis. These therapies can enhance treatment efficacy and provide comprehensive management for patients, addressing both the genetic and symptomatic elements of the disease.
- Patient Support Programs
In addition to drug development, Sionna offers patient support programs aimed at educating and guiding patients through their treatment journey. These programs include resources for disease management, access to clinical trial information, and avenues for community support to empower patients and their families.
- Research and Development Collaborations
Sionna Therapeutics actively seeks collaborations with academic institutions and research organizations to further advance the understanding of cystic fibrosis. By engaging in collaborative R&D, the company aims to explore new avenues of treatment and foster innovation in the biopharmaceutical landscape.
Contact Information
